TLDR
- Atai merges with Beckley Psytech to form mental health innovator AtaiBeckley.
- BPL-003 earns FDA Breakthrough tag, Phase 3 trials set for 2026 launch.
- New leadership drives next-gen psychedelic drug development programs.
- $150M offering boosts cash runway, funding operations through 2029.
- Despite share dip, AtaiBeckley eyes rapid growth in psychedelic medicine.
Atai Life Sciences N.V. (NASDAQ: ATAI) shares fell 13.9%, ending the session at $4.55 amid significant corporate developments.
Atai Life Sciences N.V., ATAI
The drop followed the announcement of a strategic all-share merger with Beckley Psytech, forming the new entity AtaiBeckley. The newly combined biopharma company projects a strong clinical roadmap and financial base.
AtaiBeckley Launches with Advanced Psychedelic Pipeline
AtaiBeckley begins operations with a robust lineup of psychedelic-based drug candidates focused on treatment-resistant mental health conditions. Its lead asset, BPL-003, is a nasal spray formulation of mebufotenin benzoate targeting rapid relief for treatment-resistant depression. The U.S. FDA has granted Breakthrough Therapy designation for BPL-003, supporting its potential for significant clinical benefit.
The company expects to meet with the FDA soon for an End-of-Phase 2 discussion to finalize Phase 3 plans. Management plans to launch Phase 3 trials in the second quarter of 2026, aiming for swift development. Other assets include VLS-01, EMP-01, and novel non-hallucinogenic neuroplastogens in preclinical development.
VLS-01 is in Phase 2 testing for depression, with topline data due in late 2026. EMP-01 is being studied in adults with social anxiety disorder, with Phase 2a results expected in early 2026. These programs reflect AtaiBeckley’s focus on rapid-acting therapies for underserved psychiatric conditions.
Executive Leadership and Strategic Direction Set
The new company will be led by Dr. Srinivas Rao as Chief Executive Officer, backed by a team with psychiatric and neuroscience expertise. The executive bench includes seasoned professionals in finance, operations, R&D, legal, and clinical domains. This leadership team will guide the company’s transition from Phase 2 to pivotal trials and eventual commercialization.
Board leadership remains strong with Christian Angermayer as Chairman and Scott Braunstein as Vice Chairman and Lead Independent Director. Beckley Psytech directors Cosmo Feilding Mellen and Dr. Robert Hershberg join the AtaiBeckley board. Their combined backgrounds strengthen oversight across biotech strategy, finance, and global healthcare.
The merger also included a shareholder vote approving Atai’s redomiciliation to Delaware, expected to close by year-end. Beckley shareholders received around 105 million new shares, representing 28% of the combined company’s outstanding stock. A structured lock-up schedule governs these newly issued shares post-merger.
Solid Cash Position Supports Multi-Year Development Plans
In October 2025, Atai completed a public offering raising $150 million in gross proceeds through share issuance. The offering attracted participation from prominent healthcare-focused institutions, enhancing the company’s financial flexibility. After fees, proceeds will support pipeline advancement and key regulatory milestones.
AtaiBeckley projects that its existing cash, investments, and equivalents will fund operations through 2029. This includes support for Phase 3 studies, topline data releases, and early-stage program development. The company is well-capitalized to sustain growth and execute its ambitious drug development timeline.
With a new identity, proven science, and a stable financial base, AtaiBeckley plans to accelerate innovation in mental health treatments. The sharp stock decline underscores near-term volatility, but the long-term vision remains focused on scalable psychedelic therapeutics.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
